drugset / Trial / NCT00170872
6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study tested the safety, tolerability and efficacy of lumiracoxib - a COX-2 inhibitor- in patients with primary knee osteoarthritis or rheumatoid arthritis.
Timeline
- Start
- 2004-11
- Primary completion
- 2005-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lumiracoxib | Small molecule | 200 mg | — |